Lisata Therapeutics, Inc. ( (LSTA) ) has released its Q3 earnings. Here is a breakdown of the information Lisata Therapeutics, Inc. presented to its investors.
Lisata Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing innovative therapies for advanced solid tumors and other serious diseases, with a unique emphasis on its product candidate, certepetide. In its third quarter of 2024, Lisata Therapeutics reported significant progress in its development portfolio, with multiple clinical and preclinical trials evaluating certepetide across a range of solid tumors and conditions. The company noted a decrease in operating expenses to $5.3 million, a reduction in research and development costs to $2.5 million, and a net loss of $4.9 million for the quarter. Lisata has a robust financial position with approximately $35.9 million in cash and securities, which is expected to fund operations into early 2026. Looking forward, the company anticipates a data-rich 2025 with several key clinical trial readouts, positioning it for potential advancements in its therapeutic offerings.
